Skip to content
http://lifestyle.lmcordoba.com.ar/
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Cellectis Inc.
Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress
June 11, 2026
Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL
June 9, 2026
Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026
May 25, 2026
Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress
May 24, 2026
Cellectis Reports Financial Results for the First Quarter 2026
May 24, 2026
Cellectis to Report First Quarter Financial Results on May 11, 2026
May 22, 2026
Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting
May 21, 2026
Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform
April 28, 2026
Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
March 12, 2026